BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. <i>Pharmaceuticals</i> 2025, <i>18</i>, 185.
This paper is a commentary responding to a previously published literature and patent review by Józwiak et al. (Pharmaceuticals 2025) that raised concerns about BPC 157, a stable synthetic gastric pentadecapeptide. The authors defend BPC 157's therapeutic profile, arguing that the reviewed concerns — specifically that it promotes pathological angiogenesis, elevates nitric oxide (NO) and eNOS toward damaging free radical formation, and may contribute to tumorigenesis or neurodegenerative diseases — are speculative and contradicted by existing preclinical evidence. The authors frame BPC 157 as a cytoprotective agent rooted in Robert's and Szabo's cytoprotection concept, emphasizing its alleged pleiotropic effects across organ systems. They argue that BPC 157 modulates rather than indiscriminately amplifies angiogenesis and the NO system, citing animal model studies on wound healing, corneal transparency, anti-tumor effects (per Folkman's concept), and counteraction of Parkinson's- and Alzheimer's-like disturbances in mice and rats. The paper reports a high safety profile (LD50 not achieved in animal studies). Key limitations include that this is a narrative commentary relying heavily on preclinical data, with no new human clinical trial data presented and no controlled experimental methodology introduced.
Why this grade: This is a narrative commentary/rebuttal piece that synthesizes existing preclinical (animal and in vitro) evidence without presenting new human clinical trial data, limiting its direct evidentiary value for human efficacy claims.
The healing issue is a central, not completely understood, problem in pharmacology, approached by many concepts. One of the most well-known is Robert's and Szabo's concept of cytoprotection, which holds innate cell (epithelial (Robert), endothelial (Szabo)) integrity, protection/maintenance/reestablishing in the stomach to be translated to other organ therapy (cytoprotection→organoprotection) via cytoprotection agent's effect. Thereby, we defend stable gastric pentadecapeptide BPC 157 therapy, efficacy, pleiotropic beneficial effects along with high safety (LD1 not achieved) against Józwiak and collaborators' review speculating its negative impact, speculation of angiogenesis toward tumorogenesis, increased NO and eNOS, toward damaging free radicals formation, and neurodegenerative diseases (Parkinson's disease and Alzheimer's disease). Contrarily, in wound healing and general healing capabilities as reviewed, as a cytoprotective agent, and native cytoprotection mediator, BPC 157 controls angiogenesis and the NO-system healing functions, and counteracts the pathological presentation of neurodegenerative diseases in acknowledged animal models (i.e., Parkinson's disease and Alzheimer's disease), and presents prominent anti-tumor potential, in vivo and in vitro. BPC 157 resolved cornea transparency maintenance, cornea healing "angiogenic privilege" (vs. angiogenesis/neovascularization/tumorogenesis), does not produce corneal neovascularization, but rather opposes it, and per Folkman's concept, it demonstrates anti-tumor effect in vivo and in vitro. BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances. Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.